(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 16.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Aurinia Pharmaceuticals's revenue in 2026 is $283,055,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $43,860,477,423, with the lowest AUPH revenue forecast at $39,423,235,854, and the highest AUPH revenue forecast at $47,959,972,706. On average, 9 Wall Street analysts forecast AUPH's revenue for 2027 to be $50,983,732,768, with the lowest AUPH revenue forecast at $45,489,371,916, and the highest AUPH revenue forecast at $63,588,051,868.
In 2028, AUPH is forecast to generate $59,559,031,204 in revenue, with the lowest revenue forecast at $51,473,065,971 and the highest revenue forecast at $78,170,979,135.